Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-04-08
2008-04-08
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S172100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220
Reexamination Certificate
active
10892789
ABSTRACT:
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3antagonists.
REFERENCES:
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5112946 (1992-05-01), Maione et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 5262520 (1993-11-01), Plow et al.
patent: 5575815 (1996-11-01), Slepian et al.
patent: 5578704 (1996-11-01), Kim
patent: 5652109 (1997-07-01), Kim
patent: 5652110 (1997-07-01), Kim
patent: 5677181 (1997-10-01), Parish
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5849692 (1998-12-01), Jonczyk et al.
patent: 5866540 (1999-02-01), Jonczyk et al.
patent: 5874081 (1999-02-01), Parish
patent: 5968902 (1999-10-01), Scarborough et al.
patent: 5981478 (1999-11-01), Ruoslahti et al.
patent: 576898 (1994-01-01), None
patent: 578083 (1994-01-01), None
patent: 0 770 622 (1997-05-01), None
patent: 1 334 730 (2003-08-01), None
patent: WO89/05155 (1989-06-01), None
patent: 89/06536 (1989-07-01), None
patent: 8906356 (1989-07-01), None
patent: 9320229 (1993-10-01), None
patent: WO 94/10331 (1994-05-01), None
patent: 95/14714 (1995-06-01), None
patent: 95/28426 (1995-10-01), None
patent: 97/14716 (1997-04-01), None
Davis, et al., “Identification of a Role of the Vitronectin Receptor and Protein Kinase C in the Induction of Endothelial Cell Vascular Formation”,J. Cell. Biochem., 51: 206-218 (1993).
Folkman, et al., “Angiogenic Factors”,Science, 235: 442-447 (1987).
Moses, et al., “Identification of an Inhibitor of Neovascularization from Cartilage”,Science, 248: 1408-1410 (1990).
Folkman, et al., “Inhibition of Angiogenesis”,Cancer Biology, 3: 89-96 (1992).
Blood, et al., “Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis”,Bioch. Biophys. Acta., 1032: 89-118 (1990).
Ingber, et al., “Inhibition of Angiogenesis Through Modulation of Collagen Metabolism”,Lab. Invest., 59: 44-51 (1988).
Aumailley, et al., “Arg-Gly-Asp Constrained within Cyclic Pentapeptides”,FEBS Letts., 291: 50-54 (1991).
Choi, et al., “Inhibition of Neointimal Hyperplasia by Blocking αvβ3 Integrin With a Small Peptide Antagonist GpenGRGDSPCA”,J. Vasc. Surg., 19: 125-134 (1994).
Smith, et al., “Interaction of Integrins αvβ3 and Glycoprotein IIb-IIIa with Fibrinogen”,J. Biol. Chem., 265: 12267-12271.
Nicosia, et al., “Inhibition of Angiogensis In Vitro by Arg-Gly-Asp-Containing Synthetic Peptide”,Am. J. Pathol., 138: 829-833 (1991).
Cheresh, et al., “Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen and von Willebrand Factor”,J. Biol. Chem., 262: 17703-17711 (1987).
Leavesley, et al., “Integrin β1-and β3-mediated Endothelial Cell Migration is Triggered Through Distinct Signaling Mechanism”,J. Cell Biol., 121: 163-170 (1993).
Swerlick, et al., “Expression and Modulation of the Vitronectin Receptor on Human Dermal Microvascular Endothelial Cells”,J. Invest. Derm., 99: 715-722 (1992).
Brooks, et al., “Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis”,J. Cell Biol., 122: 1351-1359 (1993).
Nip, et al., “Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin αvβ3to Adhere to Lymph Node Vitronectin”,J. Clin. Invest. 90: 1406-1413 (1992).
Jackson, et al., “Isolation and Propagation of Endothelial Cells Derived from Rheumatoid Synovial Microvasculature”,Ann. of the Rheu. Dis. 48: 733-736 (1989).
Waldman, Thomas, A., “Monoclonal Antibodies in Diagnosis and Therapy”,Science 252: 1657-1662 (1991).
Brooks, et al., “Requirement of Vascular Integrin αvβ3for Angiogenesis”,Science 264: 569-570 (1994).
Chuntharapai, et al., “Blocking Monoclonal Antibodies to αVβ3 Integrin: A Unique Epitope of a αVβ3 Integrin is Present on Human Osteoclasts”,Exper. Cell Res. 205: 345-352 (1993).
Osband, et al., “Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy”,Imm. Today 11(6): 193-195 (1990).
Ausprunk, et al., “Vascularization of Normal and Neoplastic Tissues Grafted to the Chick Chorioallantois”,Amer. J. of Path. 79(3): 597-610 (1975).
Cheresh, et al., “Recognition of Distinct Adhesive Sites on Fibrinogen by Related Integrins on Platelets and Endothelial Cells”,Cell 58: 945-953 (1989).
D'Amato, et al., “Thalidomide is an Inhibitor of Angiogenesis”,Proc. Natl. Acad. Sci. USA 91: 4082-4085 (1994).
Leibovich, et al., “Macrophage-induced Angiogenesis is Mediated by Tumour Necrosis Factor-α”,Nature 329.: 630-632 (1987).
Pfaff, et al., “Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by αIibβ3, and α5β1 Integrins”,J. of Biol. Chem. 269(32): 20233-20238 (1994).
Yan, et al., “Human/Severe Combined Immunodeficient Mouse Chimeras: An Experimental in Vivo Model System to Study the Regulation of Human Endothelial Cell-Leukocyte Adhesion Molecules”,J. Clin. Invest. 91: 986-996 (1993).
Gurrath, et al., “Conformation/Activity Studies of Rationally Designed Potent Anti-Adhesive RGD Peptides”,Eur. J. Biochem 210: 911-921 (1992).
Leven, et al., “Extracellular Matrix Stimulation of Guinea Pig Megakaryocyte Proplatelet Formation in vitro Is Mediated Through the Vitronectin Receptor”,Exp. Hematol. 20: 1316-1322 (1992).
Lafrenie, et al., “Up-regulated Biosynthesis and Expression of Endothelial Cell Vitronectin Receptor Enhances Cancer Cell Adhesion”,Canc. Res. 52: 2202-2208 (1992).
Klein, et al., “Basic Fibroblast Growth Factor Modulates Integrin Expression in Microvascular Endothelial Cells”,Mol. Bio. of the Cell 4: 973-982 (1993).
Christofanilli, et al., “Angiogenesis Modulation In Cancer Research: Novel Clinical Approaches”,Nature Reviews 1: 415-426 (2002).
Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994,Circulation, 90(5):2203-2205.
Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996,Eur. J. Cancer, 32A(1):152-159.
Aimes, et al. Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, Biochem J., 300:729-736.
Friedlander, et al., Definition of two angiogenic pathways by distinct αv integrins, 1995,Science, 270:1500-1502.
Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αIIbβ3, αvβ3 and α5β1 and in cell adhesion inhibition, 1994,Cell Adhes. Commun., 2(6):491-501.
Smith, et al., Interaction of integrins αvβ3 and glycoprotein IIb-IIIa with fibrinogen, 1990,J. Biol. Chem., 265:12267-12271.
Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on a melanoma cells,Antibody, Immunoconjugates, and Radiopharmaceuticals, 1991, 4(2):99-106.
Ossowski, et al., Experimental model for quantitative study of metastasis, 1980,Cancer Res., 40:2300-2309.
Drake, et al., A antagonist of integrin αvβ3 prevent maturation of blood vessels during embryonic neovascularization, 1995,J. Cell Sci., 108:2655-2661.
Hammes, et al., Subcutaneous injection of a cyclic peptide a
Brooks Peter C.
Cheresh David A.
Fitting Thomas
Gambel Phillip
The Scripps Research Institute
Wang Hugh
LandOfFree
Methods of treating arthritis and diabetic retinopathy with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating arthritis and diabetic retinopathy with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating arthritis and diabetic retinopathy with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3927980